«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 18

Page:

3432-3436

Research Field:

Publishing date:

Info

Title:

Comparison of the efficacy of venetoclax combined azacitidine regimen and combination of decitabine and CAG regimen in acute myeloid leukemia unfit for standard chemotherapy

Author(s):

SUN Li¹; YE Shaojie²; ZHOU Nan¹; CUI Weiguang¹; QI Jiaxu¹; LIU Xiaojun¹; LUO Jianmin¹; YANG Lin¹

1.Department of Hematology,the Sencond Hospital of Hebei Medical University,Key Laboratory of Hematology,Hebei Shijiazhuang 050000,China;2.Department of Hematology,Affiliated Hospital of Hebei University,Hebei Baoding 071000,China.

Keywords:

leukemia; myeloid; acute; venetoclax; antineoplastic combined chemotherapy protocols

PACS:

R733.71

DOI:

10.3969/j.issn.1672-4992.2023.18.018

Abstract:

Objective£ºTo compare the efficacy and safety of venetoclax combined with azacitidine (VA) regimen and combination of decitabine(DAC) and CAG£¨cytosine arabinoside+aclacinomycin+granulocyte colony stimulating factor£© regimen in newly diagnosed acute myeloid leukemia (AML) patients who were unfit for intensive chemotherapy.Methods£ºClinical data of newly diagnosed AML patients who were unfit for intensive chemotherapy admitted to our hospital from 2019.07 to 2022.07 were collected.The complete response rate (CR),composite complete response rate (cCR),overall response rate (ORR),measurable residual disease (MRD),event-free survival rate (EFS),overall survival rate (OS),and incidence of adverse events were analyzed retrospectively.The efficacy among different subgroups were assessed.Results£ºThe ORR rate of VA regimen was significantly higher than combination of DAC and CAG regimen.IDH1/2 mutation patients in VA regimen had significantly higher rate of CR£¬cCR and ORR than those in combination of DAC and CAG regimen.Patients with DNMT3A mutation showed significantly higher MRD negative rate in VA regimen than those received combination of DAC and CAG regimen.Patients with FLT3 mutation in VA regimen had longer OS than combination of DAC and CAG regimen.Conclusion£ºVA regimen demonstrated significantly superior ORR rate than combination of DAC and CAG regimen.Patients with IDH1/2,DNMT3A or FLT3 mutation were likely to benefit more in VA regimen than in combination of DAC and CAG regimen.

References:

£Û1£ÝLAGADINOU D ELENI,ZOUMBOS C NICHOLAS,SPYRIDONIDIS ALEXANDROS.Challenges in treating older patients with acute myeloid leukemia£ÛJ£Ý.J Oncol,2010,2010:943823.
£Û2£ÝAMER M ZEIDAN,WANG R,WANG XY,et al.Clinical outcomes of older patients with AML receiving hypomethylating agents:a large population-based study in the United States£ÛJ£Ý.Blood Adv,2020,4(10):2192-2201.
£Û3£ÝRORY M SHALLIS,WANG R,AMY DAVIDOFF,et al.Epidemiology of acute myeloid leukemia:Recent progress and enduring challenges£ÛJ£Ý.Blood Rev,2019,36:70-87.
£Û4£ÝF FERRARA,G BAROSI,A VENDITTI,et al.Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia:a project of SIE,SIES and GITMO group on a new tool for therapy decision making£ÛJ£Ý.Leukemia,2013,27(5):997-999.
£Û5£ÝDANIEL A ARBER,ATTILIO ORAZI,ROBERT HASSERJIAN,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasmsand acute leukemia£ÛJ£Ý.Blood,2016,127(20):2391-2405.
£Û6£ÝD¦ZHNER H,ESTEY E,GRIMWADE D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel£ÛJ£Ý.Blood,2017,129(4):424-447.
£Û7£ÝCOURTNEY D DINARDO,ANDREW H WEI.How I treat acute myeloid leukemia in the era of new drugs£ÛJ£Ý.Blood,2020,135(2):85-96.
£Û8£ÝÖлªÒ½Ñ§»áѪҺѧ·Ö»á°×Ѫ²¡ÁÜ°ÍÁöѧ×é.Öйú³ÉÈ˼±ÐÔËèϵ°×Ѫ²¡£¨·Ç¼±ÐÔÔçÓ×Á£Ï¸°û°×Ѫ²¡£©ÕïÁÆÖ¸ÄÏ£¨2021Äê°æ£©£ÛJ£Ý.ÖлªÑªÒºÑ§ÔÓÖ¾,2021,42(8):617-623. Leukemia & Lymphoma Group,Chinese Society of Hematology,Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)£ÛJ£Ý.Chinese Journal of Hematology,2021,42(8):617-623.
£Û9£ÝSANGEETHA VENUGOPAL,ABHISHEK MAITI,COURTNEY D DINARDO,et al.Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia£ÛJ£Ý.Am J Hematol,2021,96(5):E154-E157.
£Û10£ÝMING HONG,HAN ZHU,QIAN SUN,et al.Decitabine in combination with low-dose cytarabine,aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML£ÛJ£Ý.Aging (Albany NY),2020,12(7):5792-5811.
£Û11£ÝCD DINARDO,IS TIONG,A QUAGLIERI,et al.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML£ÛJ£Ý.Blood,2020,135(11):791-803.
£Û12£ÝBIANCA R SCHENLL,KATJA SEIPEL,ULRIKE BACHER,et al.Rebound thrombocytosis after induction chemotherapy is a strong biomarker for favorable outcome in AML patients£ÛJ£Ý.Hemasphere,2019,3(2):e180.
£Û13£ÝTAMER A OTHMAN,MATTHEW MEI,JIANYING ZHANG,et al.Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents£ÛJ£Ý.Am J Hematol,2021,96(5):E140-E143.
£Û14£ÝJIAYU HUANG,HUIHUI ZHAO,MING HONG,et al.Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia£ÛJ£Ý.BMC Cancer,2018,18(1):1269.
£Û15£ÝÍõÅô,ÕŶΡ,½—²çù£¬µÈ.άÄοËÀ­ÁªºÏ°¢Ôú°ûÜÕÓëµØÎ÷Ëû±õÁªºÏÔ¤¼¤·½°¸ÖÎÁÆÀÏÄ긴·¢¼±ÐÔËèϵ°×Ѫ²¡µÄÁÆЧ¼°°²È«ÐԱȽϵijõ²½¹Û²ì£ÛJ£Ý.ÖлªÄÚ¿ÆÔÓÖ¾,2022,61(02):157-163. WANG P,ZHANG LW,LU CQ,et al.Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia£ÛJ£Ý.Chinese Journal of Internal Medicine,2022,61(02):157-163.

Memo

Memo:

¹ú¼ÒѪҺϵͳ¼²²¡ÁÙ´²Ò½Ñ§Ñо¿ÖÐÐÄת»¯Ñо¿¿ÎÌâ×ÊÖúÏîÄ¿£¨±àºÅ£º2021WWB07£©£»ºÓ±±Ê¡×ÔÈ»¿Æѧ»ù½ð×ÊÖúÏîÄ¿£¨±àºÅ£ºH2019206713,H2018206035£©£»ºÓ±±Ê¡Ò½Ñ§¿ÆѧÑо¿Öصã¿ÎÌâ¼Æ»®×ÊÖúÏîÄ¿£¨±àºÅ£º20170068£©

Common functions

Last Update: 1900-01-01